By coating tiny gel beads with lung-derived stem cells and then allowing them to self-assemble into the shapes of the air sacs found in human lungs, researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have succeeded in creating three-dimensional lung “organoids.” The laboratory-grown lung-like tissue can be used to study diseases including idiopathic pulmonary fibrosis, which has traditionally been difficult to study using conventional methods.
“While we haven’t built a fully functional lung, we’ve been able to take lung cells and place them in the correct geometrical spacing and pattern to mimic a human lung,” said Dr. Brigitte Gomperts, an associate professor of pediatric hematology/oncology and the study’s lead author.
Idiopathic pulmonary fibrosis is a chronic lung disease characterized by scarring of the lungs. The scarring makes the lungs thick and stiff, which over time results in progressively worsening shortness of breath and lack of oxygen to the brain and vital organs. After diagnosis, most people with the disease live about three to five years. Though researchers do not know what causes idiopathic pulmonary fibrosis in all cases, for a small percentage of people it runs in their families. Additionally, cigarette smoking and exposure to certain types of dust can increase the risk of developing the disease.
To study the effect of genetic mutations or drugs on lung cells, researchers have previously relied on two-dimensional cultures of the cells. But when they take cells from people with idiopathic pulmonary fibrosis and grow them on these flat cultures, the cells appear healthy. “Scientists have really not been able to model lung scarring in a dish,” said Gomperts, who is a member of the UCLA Broad Stem Cell Research Center. The inability to model idiopathic pulmonary fibrosis in the laboratory makes it difficult to study the biology of the disease and design possible treatments.
Gomperts and her colleagues started with stem cells created using cells from adult lungs. They used those cells to coat sticky hydrogel beads, and then they partitioned these beads into small wells, each only 7 millimeters across. Inside each well, the lung cells grew around the beads, which linked them and formed an evenly distributed three-dimensional pattern. To show that these tiny organoids mimicked the structure of actual lungs, the researchers compared the lab-grown tissues with real sections of human lung.
“The technique is very simple,” said Dan Wilkinson, a graduate student in the department of materials science and engineering and the paper’s first author. “We can make thousands of reproducible pieces of tissue that resemble lung and contain patient-specific cells.”
Moreover, when Wilkinson and Gomperts added certain molecular factors to the 3-D cultures, the lungs developed scars similar to those seen in the lungs of people who have idiopathic pulmonary fibrosis, something that could not be accomplished using two-dimensional cultures of these cells.
Using the new lung organoids, researchers will be able to study the biological underpinnings of lung diseases including idiopathic pulmonary fibrosis, and also test possible treatments for the diseases. To study an individual’s disease, or what drugs might work best in their case, clinicians could collect cells from the person, turn them into stem cells, coax those stem cells to differentiate into lung cells, then use those cells in 3-D cultures. Because it’s so easy to create many tiny organoids at once, researchers could screen the effect of many drugs. “This is the basis for precision medicine and personalized treatments,” Gomperts said.
The Latest on: Precision medicine
via Google News
The Latest on: Precision medicine
- Precision Medicine Leader Dennis H. Langer, M.D., J.D. Joins Javelin Oncology's Board of Directorson November 24, 2020 at 12:30 pm
Javelin Oncology, Inc. announced today that the company has named Dennis H. Langer, M.D., J.D. to the company's board of directors as an independent director. Dr. Langer has served as a director of ...
- SEngine Precision Medicine to Present Data from Predictive Value of PARIS® Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer Symposiumon November 24, 2020 at 5:19 am
SEngine Precision Medicine, a precision oncology company revolutionizing cancer diagnostics and therapies by pre-testing drugs on patient-derived tumor organoids, today announced that data from a ...
- Precision Medicine Group, LLC -- Moody's assigns B2 CFR to Precision Medicine Groupon November 23, 2020 at 2:09 pm
Moody's assigns B2 CFR to Precision Medicine GroupRead the full article at Moody's ...
- Dr Michael Korn: Access to Precision Oncology Has Improved, but Remains Difficult for Some Populationson November 23, 2020 at 10:40 am
In the past, there was a greater discrepancy in access to precision oncology testing, which has closed somewhat; however, there are some disenfranchised populations who still struggle to access this ...
- Precision Medicine Market Sets 2025 Economic Growth Target with Higher Percent, a Post-COVID 19 Planon November 23, 2020 at 7:03 am
Precision Medicine Market Insight According to the 2020 Market Research Future Survey, the analysts saw 12.48% of ...
- U of U Health Names New Chair of Biomedical Informatics at School of Medicineon November 23, 2020 at 2:00 am
Yves Lussier, MD, FACMI, has been named Chair of Biomedical Informatics at University of Utah School of Medicine. The appointment, effective February 1, 2021, was announced by Michael L. Good, Senior ...
- Blackstone invests in Precision Medicine Groupon November 20, 2020 at 11:35 am
Precision Medicine and (NYSE:BX) announced that PMG has completed a major investment and recapitalization led by funds managed by Blackstone.This investment will fuel the expansion of PMG’s global ...
- Precision Medicine Group Secures Major Investment from Blackstoneon November 20, 2020 at 6:00 am
Precision Medicine Group and Blackstone today announced that PMG, a leading next-generation provider of drug development and commercialization services, has completed a major investment and ...
- UTHSC collaborates with Regeneron to advance precision medicine in the mid-southon November 19, 2020 at 12:17 pm
The University of Tennessee Health Science Center has entered into an agreement with the Regeneron Genetics Center, a subsidiary of Regeneron Pharmaceuticals, Inc., for the company to sequence DNA ...
via Bing News